Research Progress of Tumor Immunotherapy in Endometrial Cancer

doi:10.12280/gjszjk.20200409

Abstract

Abstract:

Tumor immunotherapy is a new therapy to inhibit and kill tumor by restarting and maintaining the immune function damaged in the process of tumor occurrence and development,with the advantages of small adverse reaction, high specificity, wide killing spectrum and low recurrence rate. Endometrial cancer is one of the most common malignant tumors in female reproductive system, and the incidence rate is on the rise and tends to be younger. It is a serious threat to the health of women. At present, many tumor immunotherapies have been used in clinical practice or clinical trial of endometrial cancer, including immunosuppressive checkpoint inhibitors, adoptive T cell therapy (ACT) and tumor vaccine, with the great progress. However, its clinical application is still hindered by the low response rate and drug resistance. It is of great significance to find more efficient tumor immunotherapy for the treatment of endometrial cancer. This article reviews the research progress of tumor immunotherapy in endometrial cancer, in order to provide new ideas for the treatment of endometrial cancer.

Key words: Immunotherapy, Neoplasms, Endometrial neoplasms, Therapy, Vaccines

ZHU Meng-di, ZHAO Guo-yun, YUAN Jing, SUN Yu-hui. Research Progress of Tumor Immunotherapy in Endometrial Cancer[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(2): 172-176.

References 30

[1]	Silva JL, Paulino E, Dias MF, et al. Endometrial cancer: redefining the molecular-targeted approach[J]. Cancer Chemother Pharmacol, 2015,76(1):1-11. doi: 10.1007/s00280-015-2758-z. doi: 10.1007/s00280-015-2758-z URL pmid: 25935126
[2]	Iacovelli R, Ciccarese C, Facchini G, et al. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis[J]. Target Oncol, 2020,15(5):691. doi: 10.1007/s11523-020-00746-6. doi: 10.1007/s11523-020-00746-6 URL pmid: 32857328
[3]	Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J]. N Engl J Med, 2018,378(21):1976-1986. doi: 10.1056/NEJMoa1716078. doi: 10.1056/NEJMoa1716078 URL pmid: 29658848
[4]	Moreira RS, Bicker J, Musicco F, et al. Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges[J]. Life Sci, 2020,240:117093. doi: 10.1016/j.lfs.2019.117093. doi: 10.1016/j.lfs.2019.117093 URL pmid: 31760100
[5]	Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for?Advanced Nonsquamous Non-Small Cell Lung Cancer[J]. J Thorac Oncol, 2019,14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. doi: 10.1016/j.jtho.2018.08.004 URL pmid: 30138764
[6]	Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition[J]. Oncoimmunology, 2017,6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. doi: 10.1080/2162402X.2016.1264565 URL pmid: 28344870
[7]	Kim J, Kim S, Lee HS, et al. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer[J]. Gynecol Oncol, 2018,149(2):381-387. doi: 10.1016/j.ygyno.2018.02.013. doi: 10.1016/j.ygyno.2018.02.013 URL pmid: 29572029
[8]	Dizon DS, Dias-Santagata D, Bregar A, et al. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation[J]. Oncologist, 2018,23(6):650-653. doi: 10.1634/theoncologist.2017-0526. doi: 10.1634/theoncologist.2017-0526 URL pmid: 29472312
[9]	Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer[J]. J Clin Oncol, 2020,38(26):2981-2992. doi: 10.1200/JCO.19.02627. doi: 10.1200/JCO.19.02627 URL pmid: 32167863
[10]	Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study[J]. J Clin Oncol, 2017,35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. doi: 10.1200/JCO.2017.72.5952 URL pmid: 28489510
[11]	Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer[J]. J Clin Oncol, 2019,37(30):2786-2794. doi: 10.1200/JCO.19.01021. doi: 10.1200/JCO.19.01021 URL pmid: 31461377
[12]	Mittica G, Ghisoni E, Giannone G, et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity[J]. Oncotarget, 2017,8(52):90532-90544. doi: 10.18632/oncotarget.20042. doi: 10.18632/oncotarget.20042 URL pmid: 29163851
[13]	Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy[J]. Genes Cancer, 2018,9(5/6):176-189. doi: 10.18632/genesandcancer.180. doi: 10.18632/genesandcancer.v9i5-6 URL
[14]	Moore M, Ring KL, Mills AM. TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers[J]. Mod Pathol, 2019,32(8):1168-1179. doi: 10.1038/s41379-019-0251-7. doi: 10.1038/s41379-019-0251-7 URL pmid: 30926882
[15]	Barrington DA, Dilley SE, Smith HJ, et al. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis[J]. Gynecol Oncol, 2019,153(2):381-384. doi: 10.1016/j.ygyno.2019.02.013. doi: 10.1016/j.ygyno.2019.02.013 URL pmid: 30808517
[16]	Yu X, Huang X, Chen X, et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy[J]. MAbs, 2019,11(6):1139-1148. doi: 10.1080/19420862.2019.1629239. doi: 10.1080/19420862.2019.1629239 URL pmid: 31242068
[17]	Met Ö, Jensen KM, Chamberlain CA, et al. Principles of adoptive T cell therapy in cancer[J]. Semin Immunopathol, 2019,41(1):49-58. doi: 10.1007/s00281-018-0703-z. doi: 10.1007/s00281-018-0703-z URL pmid: 30187086
[18]	Xiao Z, Wang CQ, Zhou MH, et al. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials[J]. Int Immunopharmacol, 2018,61:363-375. doi: 10.1016/j.intimp.2018.06.012. doi: 10.1016/j.intimp.2018.06.012 URL pmid: 29945024
[19]	Zhang Y, Qi Y, Wang A, et al. Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review[J]. Onco Targets Ther, 2017,10:4687-4690. doi: 10.2147/OTT.S147714. doi: 10.2147/OTT.S147714 URL pmid: 29026316
[20]	Hu Z, Zheng X, Jiao D, et al. LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer[J]. Mol Ther Oncolytics, 2020,17:361-370. doi: 10.1016/j.omto.2020.04.008. doi: 10.1016/j.omto.2020.04.008 URL pmid: 32405534
[21]	Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers[J]. Mol Ther, 2017,25(5):1248-1258. doi: 10.1016/j.ymthe.2017.03.010. doi: 10.1016/j.ymthe.2017.03.010 URL pmid: 28366766
[22]	Jindal V, Arora E, Masab M, et al. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice[J]. Med Oncol, 2018,35(6):84. doi: 10.1007/s12032-018-1145-0. doi: 10.1007/s12032-018-1145-0 URL pmid: 29728788
[23]	Rodriguez-Garcia A, Sharma P, Poussin M, et al. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies[J]. Mol Ther, 2020,28(2):548-560. doi: 10.1016/j.ymthe.2019.11.028. doi: 10.1016/j.ymthe.2019.11.028 URL pmid: 31870622
[24]	Zhang J, Wang L. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review[J]. Technol Cancer Res Treat, 2019,18:1533033819831068. doi: 10.1177/1533033819831068. doi: 10.1177/1533033819831068 URL pmid: 30798772
[25]	Kosti P, Maher J, Arnold JN. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors[J]. Front Immunol, 2018,9:1104. doi: 10.3389/fimmu.2018.01104. doi: 10.3389/fimmu.2018.01104 URL pmid: 29872437
[26]	Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity[J]. Cancer Immunol Immunother, 2017,66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. doi: 10.1007/s00262-017-2034-7 URL pmid: 28660319
[27]	Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy[J]. Mol Cancer, 2019,18(1):128. doi: 10.1186/s12943-019-1055-6. doi: 10.1186/s12943-019-1055-6 URL pmid: 31443694
[28]	Coosemans A, Vanderstraeten A, Tuyaerts S, et al. Wilms′ Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial[J]. Anticancer Res, 2013,33(12):5495-5500.
[29]	Li FQ, Liu Q, Han YL, et al. Sperm protein 17 is highly expressed in endometrial and cervical cancers[J]. BMC Cancer, 2010,10:429. doi: 10.1186/1471-2407-10-429. doi: 10.1186/1471-2407-10-429 URL pmid: 20712874
[30]	Brown TA, Byrd K, Vreeland TJ, et al. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients[J]. Cancer Med, 2019,8(10):4678-4687. doi: 10.1002/cam4.2378. doi: 10.1002/cam4.2378 URL pmid: 31274231